Publication: The unique CARWL score stratifies locally advanced nasopharyngeal cancer patients receiving concurrent chemoradiotherapy into risk groups for radiation-induced trismus
Program
KU-Authors
Selek, Uğur
Durankuş, Nilüfer Kılıç
Şenyürek, Şükran
KU Authors
Co-Authors
Somay, Efsun
Bascil, Sibel
Ozturk, Duriye
Topkan, Erkan
Advisor
Publication Date
Language
Type
Journal Title
Journal ISSN
Volume Title
Abstract
Purpose To determine the utility of the novel CARWL score, which integrates C-reactive protein-to-albumin ratio (CAR) and significant weight loss (SWL), in stratifying the locally advanced nasopharyngeal carcinoma (LA-NPC) patients into significantly different radiation-induced trismus (RIT) risk groups following definitive C-CRT. Patients and methods This retrospective study analyzed the medical records of 286 LA-NPC patients who received C-CRT between January 2010 and December 2022. The maximum mouth opening (MMO) was measured before the C-CRT, at 1, 3, 6, 9, and 12 months, and every 6 months after that during the follow-up. Additionally, the CAR value just before the commencement of C-CRT and SWL defined as a weight loss > 5% in the preceding six months were documented for each patient. RIT was defined as a MMO <= 35 mm. Results The optimal CAR cut-off was 3.03 (area under the curve: 87.3%;sensitivity: 82.6%;specificity: 80.9%, J-index: 0.635), using receiver operating characteristic (ROC) curve analysis, with RIT incidence being the event. We stratified the patients into three CARWL score groups. CARWL-0: CAR < 3.0 and WL <= 5.0% (N = 92), CARWL-1: CAR < 3.0 and WL > 5.0% or CAR >= 3.0 (N = 99), and WL <= 5.0% and CARWL-2: CAR > 3.0 and WL > 5.0% (N = 95). The incidence of RIT increased significantly across CARWL score groups (8.7% for CARWL-0, 23.2% for CARWL-1, and 44.2% for CARWL-2;P < 0.001). Conclusion The current study indicated that the novel CARWL scoring system is efficient in precisely stratifying LA-NPC patients into distinct RIT risk groups after C-CRT.
Source:
DISCOVER ONCOLOGY
Publisher:
Springer
Keywords:
Subject
Oncology, Endocrinology